Abstract

Biallelic mutations in ACP5, encoding tartrate-resistant acid phosphatase (TRACP), have recently been identified to cause the inherited immuno-osseous disorder, spondyloenchondrodysplasia (SPENCD). This study was undertaken to characterize the eight reported missense mutations in ACP5 associated with SPENCD on TRACP expression. ACP5 mutant genes were synthesized, transfected into human embryonic kidney (HEK-293) cells and stably expressing cell lines were established. TRACP expression was assessed by cytochemical and immuno-cytochemical staining with a panel of monoclonal antibodies. Analysis of wild (WT) type and eight mutant stable cell lines indicated that all mutants lacked stainable enzyme activity. All ACP5 mutant constructs were translated into intact proteins by HEK-293 cells. The mutant TRACP proteins displayed variable immune reactivity patterns, and all drastically reduced enzymatic activity, revealing that there is no gross inhibition of TRACP biosynthesis by the mutations. But they likely interfere with folding thereby impairing enzyme function. TRACP exists as two isoforms. TRACP 5a is a less active monomeric enzyme (35kD), with the intact loop peptide and TRACP 5b is proteolytically cleaved highly active enzyme encompassing two subunits (23 kD and 16 kD) held together by disulfide bonds. None of the mutant proteins were proteolytically processed into isoform 5b intracellularly, and only three mutants were secreted in significant amounts into the culture medium as intact isoform 5a-like proteins. Analysis of antibody reactivity patterns revealed that T89I and M264K mutant proteins retained some native conformation, whereas all others were in "denatured" or "unfolded" forms. Western blot analysis with intracellular and secreted TRACP proteins also revealed similar observations indicating that mutant T89I is amply secreted as inactive protein. All mutant proteins were attacked by Endo-H sensitive glycans and none could be activated by proteolytic cleavage in vitro. In conclusion, determining the structure-function relationship of the SPENCD mutations in TRACP will expand our understanding of basic mechanisms underlying immune responsiveness and its involvement in dysregulated bone metabolism.

Highlights

  • IntroductionTartrate-resistant acid phosphatase (type-5 acid phosphatase; tartrate-resistant acid phosphatase (TRACP), EC 3.1.3.2.) is a ~35 kD metalloenzyme with a mixed valency di-iron center, required for catalytic activity [1]

  • Tartrate-resistant acid phosphatase is a ~35 kD metalloenzyme with a mixed valency di-iron center, required for catalytic activity [1]

  • In the homozygous or heterozygous state, these mutations result in tartrate-resistant acid phosphatase (TRACP) deficiency in cells and serum resulting in a complex heritable disease SPENCD [12,13,14]

Read more

Summary

Introduction

Tartrate-resistant acid phosphatase (type-5 acid phosphatase; TRACP, EC 3.1.3.2.) is a ~35 kD metalloenzyme with a mixed valency di-iron center, required for catalytic activity [1]. TRACP is expressed primarily by differentiated cells of the mononuclear phagocyte system including osteoclasts, macrophages and dendritic cells (DC) [2]. It has a long history of clinical relevance as a cytochemical marker for hairy cell leukaemia, and as a serum marker for osteoclastic bone resorption and, more recently, chronic inflammation [3]. TRACP exists as two isoforms, which are derived by differential post-translational processing of a central regulatory loop peptide [4]. Isoform 5b is released into the circulation with other matrix products during bone resorption, serving as a marker for osteoclast activity [6]. The regulatory signals that govern this differential processing are not fully understood

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.